In patients with newly diagnosed AML treated with 10-day decitabine and VEN, one study found that TP53 mutations conferred a reduced ORR compared to wild-type TP53 (66% versus 89%, p = 0.002), with a significantly higher 60-day mortality in the TP53-mutated group (26% versus 4%, p < 0.001); the OS was significantly worse in TP53-mutated patients compared to wild-type TP53 at 5.2 months versus 19.4 months, respectively [110]. The gene discussed is TP53; the disease is acute myeloid leukemia.